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Abstract Carbonic anhydrase VA (CAVA) is a mito-
chondrial enzyme that catalyzes the reversible hydration of
CO2 to produce HCO3
- and proton. CAV is primarily
involved in several biosynthetic processes such as
ureagenesis, gluconeogenesis and lipogenesis by providing
bicarbonate ion. Here, we report a new strategy for cloning,
expression and purification for CAVA in the bacterial
system followed by its biophysical characterization. The
cDNA of CAVA, a 801 nucleotide long that encodes a
267-amino acid polypeptide of molecular mass of 30-kDa
(excluding signal peptide), was sub-cloned in the expres-
sion vector pET21c and transformed into Escherichia coli
strain BL21 (DE3) for expression. The recombinant protein
was purified in two steps by Ni–NTA and DEAE weak
anion-exchange chromatography under native condition
from the supernatant, while inclusion bodies (IBs) were
used to get protein under the denatured condition with a
relatively high yield. CAVA was purified under denatured
conditions in a single step using Ni–NTA chromatography.
SDS-PAGE showed a band of 30-kDa, which was further
confirmed as CAVA by Western blot and MALDI-TOF/
MS. We further performed enzyme activity to ensure that
both forms of purified proteins are enzymatically active.
Measurements of secondary structure of the native, dena-
tured and renatured proteins were carried out using circular
dichroism. The purified protein can be further used for
structural and biochemical studies.
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Introduction
Carbonic anhydrase V (CAV) is a mitochondrial enzyme
(Dodgson et al. 1980) that catalyzes the hydration of car-
bon dioxide to produce proton and bicarbonate. CAV exists
in two closely related mitochondrial isoform known as
carbonic anhydrase VA (CAVA) and CAVB which have a
distinct tissue distribution (Imtaiyaz Hassan et al. 2013).
CAVB is expressed in the heart, skeletal muscle, kidney,
salivary gland and spinal cord (Ghandour et al. 2000),
while CAVA is localized in the mitochondria and expres-
sed primarily in the liver (Saarnio et al. 1999). CAVA is
actively involved in several biosynthetic processes such as
ureagenesis, gluconeogenesis and lipogenesis and helps in
glucose (Dodgson and Cherian 1989; Parkkila et al. 1998),
fatty acid and urea synthesis (van Karnebeek et al. 2014).
CAV is the only mammalian CA which is compartmen-
talized in a cell organelle and it has tyrosine at 64th position
instead of histidine, a catalytic proton shuttle residue which
transfers proton from zinc-bound water to buffer (Boriack-
Sjodin et al. 1995; Vitale et al. 2007). However, the proton
shuttle transport in CAV is still not clear.
CAVA gene was localized to chromosome 16q24.3 and
an unprocessed pseudogene has been assigned to 16p12
(Nagao et al. 1995). CAVA gene is composed of 915
nucleotides encoding a 305-amino acid protein with a
molecular mass of 35-kDa. It has a hydrophobic N-terminal
mitochondrial signal sequence of 38 amino acid residues
and a catalytic domain of 267-amino acids. Based on the
effect of CA inhibitors on these processes, a physiological
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role of CAVA in the biosynthetic processes has been
suggested (Liang et al. 1993; Heck et al. 1994). In fact,
mitochondria require CAV for these metabolic processes,
and deregulation of this enzyme causes obesity (Areched-
erra et al. 2013), which is one of the most common human
diseases, because of alteration in the metabolic substrate
flux (Picard et al. 2000). Inhibition of CAVA has been
identified as a novel anti-obesity strategy, over the other
because of their serious cardiovascular or central nervous
system (CNS) side effects. Several studies have provided
insight that inhibition of CAVA with sulfonamide/sulfa-
mate drug has potential as anti-obesity (Kaul and Ritschel
1988). However, better inhibitors are needed to overcome
the problem of selectivity, since CAVA share a close
homology, with other CA isoform, to design selective
inhibitors of CAVA is challenging (Iqbal et al. 2015;
Swenson 2014).
We tried to express the full length of CAVA in the
bacterial system, but protein was unable to get solubilized.
To overcome this problem, we have sub-cloned cDNA of
CAVA into expression vector pET21c, encoding a
267-amino acid protein corresponding to the catalytic
domain only (801 nucleotides and 30-kDa). Moreover, we
have purified CAVA from both soluble supernatant and
inclusion bodies (IBs). We further optimized the purifica-
tion procedure to get the soluble proteins from inclusion
bodies which have similar structure and enzyme activity in
comparison to the protein purified from the supernatant.
The aim of the present study is to construct a prokaryotic
expression system for producing recombinant protein
which can be used for structure–function studies in future.
Materials and methods
Strains and plasmid
Clone of CAVA was purchased from PlasmID Harvard
Medical School. DH5a and BL21 (DE3) strains of E. coli
were used for cloning and expression of the protein,
respectively. E. coli cells harboring recombinant plasmid
were grown aerobically at 37 C in Luria–Bertani (Merck,
Darmstadt, Germany) broth with 100 lg/ml ampicillin
(Sigma, Saint Louis, MO, USA). Plasmid pET-21c (No-
vagen, WI, USA) was used as expression vector. Plasmid
isolation, restriction enzyme digestion, ligation and com-
petent cell preparation were carried out using standard
procedure.
Cloning of CAVA gene
The 801-bp coding region (39-305aa) was amplified by
PCR from plasmid pENTR2231 containing the CAVA
gene using forward and reverse primers 50CTAGCTAGC
TGTGCATGGCAAACCAGCAA30 and 50CGGCTCGAG
TAAGGACCTTTGCCCTCATTAG30, respectively. This
amplification generated Nhe1 and Xho1 sites on each end
of the amplified fragment and excluded the coding region
(1-38aa) for the putative signal sequence. The CAVA gene
was sub-cloned into pET21c vector with the C-terminal
His6 tag.
Expression of recombinant protein CAVA
The constructed expression vector (pET21c-CAVA) con-
taining coding region of CAVA gene was transformed into
E. coli BL21 (DE3) host cells by following the standard
protocol. Overnight culture of the expression cells from a
freshly transformed plate was inoculated in LB media,
containing 100 lg/ll ampicillin, and incubated at 37 C,
with constant agitation at 220 rpm in an incubator shaker
until the absorbance reaches 0.6 at 600 nm. The culture was
induced by 0.50 mM IPTG (Sigma, Saint Louis, USA) and
incubated for next 15 h at 16 C. Cells were centrifuged at
7000g for 10 min at 4 C. Then, cells were dissolved in
50 mM Tris–HCl buffer, pH 8.0 containing 500 mM NaCl,
5 % (v/v) glycerol, 5 mM b-mercaptoethanol, 0.1 mg/ml
lysozyme, 100 mM phenyl methane sulfonyl fluoride
(PMSF) and 1 % (v/v) triton X-100 (U. S. Biochemical
Corp). Cell lysate was sonicated on ice and centrifuged for
30 min at 13,000 rpm at 4 C. Supernatant was collected for
purification of CAVA by the nickel affinity chromatography.
Purification of CAVA under native condition
A clear supernatant was passed through Ni–NTA column
which was pre-equilibrated with a buffer (50 mM Tris–
HCl, pH 8.0, 500 mM NaCl, 5 % (v/v glycerol, 5 mM b-
mercaptoethanol, 10 mM imidazole). After binding of
protein, column was washed with 50 ml of washing buffer
(50 mM Tris–HCl, pH 8.0, 500 mM NaCl, 5 % (v/v)
glycerol, 5 mM b-mercaptoethanol, 20 mM imidazole) at
4 C. Bound protein was eluted with 300 mM imidazole.
The fractions were concentrated using Amicon Ultra 10 K
device (Merck Darmstadt, Germany) and dialyzed against
50 mM Tris–HCl pH 8.0 buffer. The dialyzed sample was
further loaded on Hi Trap DEAE FF (1 ml,
7 mm 9 25 mm) column (GE healthcare) pre-equilibrated
with 50 mM Tris–HCl buffer, pH 8.0. Bound proteins were
eluted with increasing concentration of NaCl (0–1 M
NaCl) in the 50 mM Tris–HCl pH 8.0 buffer. Elution was
controlled by Akta purifier (GE healthcare) with a flow rate
of 0.5 ml/min. CAVA eluted at 0.50 M NaCl was pooled,
concentrated and stored for further study. The purity of
protein was confirmed by sodium dodecyl sulfate-poly-
acrylamide gel electrophoresis (SDS-PAGE).
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Alternative methods of CAVA purification
We also report an alternative method of CAVA purification
as a major portion of CAVA which was expressed as
insoluble protein in the form of inclusion bodies (IBs).
Earlier, we successfully purified the protein from the sol-
uble form, but its yield was very low. To increase the yield
of CAVA protein, we have tried a number of different
methods to isolate the protein from IBs.
Preparation and solubilization of IBs
Escherichia coli cells were centrifuged, pellets were
resuspended in lysis buffer (50 mM phosphate buffer and
300 mM NaCl, pH 7.0) and lysed through sonicate, and IBs
in the cell lysate were pelleted by low-speed centrifugation.
Then, the pellet was again resuspended and washed with
milli-Q water through centrifugation thrice to remove
contaminations and got purified IBs. Solubilization of IBs
is a vital step to obtaining the maximal amount of desired
protein. We tried various denaturing conditions, such as
urea, 1 % SDS, guanidinium chloride (GdmCl) and 1 % N-
lauroylsarcosine to obtain maximum amount of our protein.
CAVA was solubilized in all conditions. We solubilized
the purified IBs with 50 mM phosphate buffer pH 7.0,
300 mM NaCl and 1 % N-lauroylsarcosine, and incubated
on rocker for 30 min. We centrifuged the solubilized IBs
for 30 min at 12,000 rpm and collected the supernatant.
Purification of recombinant CAVA from IBs
Ni–NTA column was equilibrated with equilibration buffer
(50 mM phosphate buffer pH 7.0, 50 mM NaCl and 1 %
N-lauroylsarcosine). The collected supernatant was loaded
on equilibrated Ni–NTA column. Then, the column was
washed with washing buffer (50 mM phosphate buffer pH
7.0, 50 mM NaCl and 1 % N-lauroylsarcosine and 20 mM
imidazole). The desired protein was eluted with elution
buffer (50 mM phosphate buffer pH 7.0, 50 mM NaCl and
0.5 % N-lauroylsarcosine and 300 mM imidazole). The
fractions of eluted CAVA protein were collected and
checked for homogeneity on SDS-PAGE.
Western blotting
Band of CAVA protein on SDS-PAGE was transferred
onto the nitrocellulose membrane using standard proce-
dure. Nitrocellulose membrane was blocked with 5 % non-
fatty acid milk powder in phosphate-buffered saline (PBS)
for 2 h followed by three washing. Conjugate Anti-His–
HRP antibody (Penta-His, Qiagen) was incubated with the
membranes for another 2 h and subsequently washed to
remove the unbound antibody. Blot was developed by
incubating the membrane for 2 min with 3, 30-di-
aminobenzidine (DAB) reagents (Zhongshan Biotech,
Beijing) and 200 ll hydrogen peroxide.
Mass spectrometry
To know the amino acid sequence of purified protein, we
performed matrix-assisted laser desorption/ionization time
of flight mass spectrometry (MALDI-ToF/MS). The band of
CAVA from the SDS-PAGE was excised for tryptic diges-
tion and subjected to mass spectrometer (Kratos Analytical,
Shimadzu Group Company, Japan). We used standard pro-
cedure for the sequencing of CAVA, which was described
elsewhere in detail (Hassan et al. 2007a, 2008). The peptide
mass finger prints were used to identify protein by searching
the SWISS-PROT and NCBI-nr databases using the Mascot
2.0 search engine with fragment mass tolerance of ±0.5 Da
and max missed cleavages of one (Table 1).
Enzyme activity
To confirm the active nature of the purified protein, we
performed enzyme activity of the native and renatured
CAVA molecules. The p-nitrophenyl acetate (NPA) was
used as the substrate to measure the activity of CAVA by
recording the increase of absorbance at 400 nm (Ikai et al.
1978). The reaction cuvette contained 0.1 mM p-nitro-
phenyl acetate in 50 mM Tris pH 8.0, 5 % acetonitrile and
enzyme in the concentration of 0.3 mg/ml for both CAII
and CAVA at 25 C. We have taken CAII as a positive
control for activity. Esterase activity was carried out by
following the release of nitrophenol which was measured at
400 nm by spectrophotometer (Jasco V-660, Model B
028661152) equipped with Peltier-type temperature con-
troller (ETCS-761). All spectral measurements were done
at least three times at 25 ± 0.1 C.
Circular dichroism
Secondary structure of CAVA was measured using circular
dichroism (CD) in Jasco spectropolarimeter (model J-1500)
equipped with Peltier type temperature controller. The far-
UV CD spectra (250–200 nm) were recorded at 25 ± 0.1 C
using a cuvette of 1 mm path length cell and protein con-
centration of 0.3 mg/ml (10 lM). Samples of the native and
renatured CAVA were prepared in 50 mM Tris–HCl and
50 mM phosphate buffer containing 150 mM NaCl at pH 8.0
and 7.0, respectively. Denatured sample was prepared in
phosphate buffer with 1 % N-lauroylsarcosine at pH 7.0. The
raw CD data were converted to the mean residue ellipticity,
[h] (degrees cm2 dmol-1), using the relation:
½h ¼ Mo½h=10lc ð1Þ
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where [h] is the observed ellipticity in millidegrees, Mo is
the mean residue weight of the protein, c is the concen-
tration in mg/ml, and l is the path length of the cell in
centimetre. The CD spectra were uploaded onto the K2D2
server to estimate the secondary structural content of
CAVA (Perez-Iratxeta and Andrade-Navarro 2008). This
server is based on the comparison of real and predicted
values, by means of the Pearson correlation coefficient
(r) and the root mean square deviation (RMSD) of proteins
with known three-dimensional structure. A detail of algo-
rithm is described elsewhere (Johnson 1999; McPhie 2008;
Sreerama and Woody 2000).
Results
Cloning and expression of CAVA
The CAVA gene from plasmid pENTR223 was amplified
by PCR, with Nhe1 and Xho1 site at the 50 and 30 end,
respectively. The amplified product was 801 bp long
(Fig. 1a). It was digested with same restriction enzymes
Nhe1 and Xho1, and subsequently ligated to the pET21c
Nhe1 and Xho1 backbone fragment. This clone was con-
firmed by colony PCR (Fig. 1b) and restriction digestion
with Nhe1 and Xho1 endonucleases (Fig. 1c). Constructed
plasmid was further verified by DNA sequencing (not
shown). The confirmed plasmid constructed pET21c-
CAVA was transformed into E. coli BL21 (DE3).
Recombinant protein was expressed at 16 C by inducing
with 0.5 mM IPTG. Overexpression of CAVA was clearly
indicated on SDS-PAGE with an apparent molecular
weight of 30-kDa (Fig. 2a).
Purification of CAVA under native condition
To purify proteins in biologically active form from bac-
terial system, require an optimization of expression, sol-
ubilization of IBs and refolding experiments. Here, we
expressed CAVA in E. coli BL21 (DE3). The major
portion of the protein was expressed as insoluble frac-
tions. Hence, we have purified CAVA successfully under
the native as well as denatured conditions. The recombi-
nant CAVA protein was isolated and purified to homo-
geneity at 4 C from cell extract under the native
condition. CAVA was found in the soluble bacterial
extract, and obtained after the centrifugation of sonicated
E. coli cell at 20,000g. CAVA was purified to homo-
geneity by two chromatographic steps on Ni–NTA affinity
chromatography and DEAE ion-exchange chromatogra-
phy. The eluted fractions after Ni–NTA affinity chro-
matography showed a significant level of contamination
by other proteins (Fig. 2b). Eluted fractions were pooled,
extensively dialyzed and loaded on to the DEAE anion
exchanger column to get pure CAVA. Elution profile of
DEAE anion exchanger column chromatography is shown
in Fig. 2c. Fractions of protein obtained in DEAE anion
exchanger column were subjected to SDS-PAGE to check
the purity. A clear single band was observed on SDS-
PAGE indicating the purity of CAVA (Fig. 2d). A sum-
mary of CAVA purification procedure is provided in
Table 2.
Purification of CAVA under denatured condition
To improve protein yield, we purified CAVA protein under
denatured condition from IBs because large portion of
recombinant CAVA protein was expressed there. We iso-
lated IBs from cell extract and purified by sequential
washing with milli-Q water to remove contaminants,
especially non-specific proteins and proteases. Purified IBs
of 30 kDa were checked on SDS-PAGE (Fig. 3a). We used
1 % N-lauroylsarcosine to solubilize the IBs among other
denaturants because of problems in downstream processes.
Solubilized IBs were loaded on an Ni–NTA affinity chro-
matography and purified in single chromatography step.
The purity and yield of fractions of purified CAVA were
checked on SDS-PAGE (Fig. 3b).
Table 1 List of peptide fragments obtained after trypsinization





38–63 2865.4580 2864.4507 2864.4028 17 R. SCAWQTSNNTLHPLWT
64–72 1141.6107 1140.6034 1140.6040 -0 R.QSPINIQWR.D
73–84 1430.7755 1430.7755 1429.7682 8 R.DSVYDPQLKPLR.V
169–185 1715.0111 1714.0038 1713.9665 22 K.EAVVGENGLAVIGVFLK
186–195 1160.6216 1159.6143 1159.6210 -6 K.LGAHHQTLQR.L
250–263 1529.8103 1528.8030 1528.7885 9 K.EPVEVAPSQLSAFR.T
276–290 1876.9592 1875.9519 1875.9270 13 K.MMVNNYRPLQPLMNR
291–304 1594.8141 1593.8068 1593.7899 11 R.KVWASFQATNEGTR.S
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Refolding of CAVA
Refolding of the protein is an important process to remove
excess denaturants and provide appropriate condition for
protein to spontaneously refold into correct conformation.
There is no standard protocol for refolding of proteins. We
refolded CAVA by dialyzing the solution against 50 mM
phosphate buffer pH 7.0 and 150 mM NaCl for 24 h at
4 C. Dialyzed protein was centrifuged to remove any
precipitate formed during refolding. To further check that
Fig. 1 Cloning of CAVA gene:
a amplified CAVA gene. Lane
1: Marker and Lane 2 is an
amplified product of 801 bp.
b Confirmed constructed
plasmid by colony PCR. Lane 1
is a marker and lanes 3 to 8 are
amplified products, further
confirmed by restriction
digestion. c Digested products
back bone of 5.4 kb of pET21c
and gene of CAVA of 801
nucleotides (Lane 2) and Lane 1
is a marker
Fig. 2 Purification of CAVA under native condition. a SDS-PAGE
showing the expression of recombinant CAVA protein. b SDS-PAGE
showing an eluent obtained from Ni–NTA column chromatography.
Lane 1 is flow through, lane 2 is washing with 20 mM imidazole and
lanes 3 to 9 are eluent fractions. c Elution profile of ion-exchange
chromatography. d SDS-PAGE of purified CAVA. Lane 1 is a
molecular mass marker and lane 2 shows purified CAVA
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refolded protein is enzymatically active, we performed an
enzyme assay. CAVA catalyzes the hydrolysis of p-nitro-
phenyl-acetate to p-nitrophenol, measured by recording the
increase in absorbance with time. A significant increase in
the optical density of solution at 400 nm clearly suggests
that purified native and renatured CAVA is enzymatically
active (data not shown).
Sequencing and identification
The CAVA was confirmed by Western blot (Fig. 4a) and
mass spectrometry MALDI-TOF (Fig. 4b). Mass spec-
trometry analysis identified many fragments of CAVA,
clearly indicating this protein as human mitochondrial
CAVA (Table 1). Both these studies clearly indicate that
purified protein is CAVA.
Secondary structure measurement
To estimate secondary structure contents, we performed the
far-UV CD of denatured, renatured and native CAVA
proteins at 25 C in the region of 250 to 200 nm (Fig. 5).
Spectra were analyzed to determine the secondary structure
content of the protein with available programme (Perez-
Iratxeta and Andrade-Navarro 2008). We used K2D2 ser-
ver and found the secondary structural contents of the
native CAVA as 20.2 % a-helix, 29.1 % b-sheet and
50.7 % random coil, for the renatured CAVA as 21.7 % a-
helix, 27.2 % b-sheet and 51.3 % random coil, and for the
denatured CAVA contents as 15.3 % a- helix, 21.7 % b-
sheet and 63 % random coil. The crystal structure of
human CAVA is not determined so far. However, we
calculated the secondary structure content through sec-
ondary structure prediction server and homology model-
ing and a considerable correlation was observed between
the theoretical calculation of secondary structure and
calculation of the CD data. Moreover, refolding study
clearly indicates that CAVA is a reversibly denatured
protein.
Discussion
We have successfully cloned, expressed and purified
human CAVA (CAVA), which lacks the first 38 amino
acid N-terminal residues for putative mitochondrial signal
sequence. This is the first report of human CAVA protein
purified in the bacterial system in both native and dena-
tured conditions. However, mouse mitochondrial CAVB
was successfully expressed and purified from bacterial
system, but truncated form of CAVB (CAVB) could not be
purified from the bacterial system due to its toxicity for
Fig. 3 Purification of CAVA
under denatured condition.
a SDS-PAGE showing
expression of CAVA in IBs.
Lane 1 shows a marker and lane
2 is for CAVA, b SDS-PAGE
shows an eluent obtained from
Ni–NTA column
chromatography (lanes 1–4 and
6) and lane 5 is marker
(prestained protein marker,
broad range (7–175 kDa)
Table 2 Purification summary
S. no. Purification step Volume (ml) Protein (mg/ml)b Total protein (mg) Yield (100 %)
1 E. coli cell pelleta 60 43.91 2635.02 100
2 Supernatant 56 1.428 79.968 3.034
3 Ni-affinity chromatography 15 0.136 2.04 0.077
4 Weak anion chromatography (DEAE column) 2 0.504 1.008 0.038
a From 8 g of wet weight E. coli cell pellet (from 4 litre of batch)
b Protein concentration determined by Lowry assay using BSA as a standard protein
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host (Heck et al. 1994). We compared human CAVA with
mouse CAVB, because it has 85 % homology and will try
to find out the reason why truncated form of human CAVA
is not toxic. We purified CAVA using the combination of
Ni–NTA affinity and anion exchange chromatography used
to purify recombinant protein yielded a pure and homo-
geneous protein but yield is very low under native condi-
tions. We also used alternate methods to improve yield,
prepared IBs and isolated CAVA from it under denaturing
conditions. We successfully solubilized IBs using 1 % N-
lauroylsarcosine, purified through Ni–NTA chromatogra-
phy only, single step purification and refolded into bio-
logically active form. Our yield has been improved, and it
is around 40 mg/litre. We identified and confirmed the
purified protein by Western bolting as well as MALDI-ToF
mass spectrometry. The expression and purification pro-
cedures reported in this study have provided a simple and
efficient method to obtain pure CAVA protein used for
further studies of its structure and function.
We have successfully cloned, expressed and purified
CAVA protein in E. coli. We found that purified CAVA
from their IBs under denatured condition is a good
approach as we got high purity and concentration in single
step. We are working on structure-based drug design
(Hassan et al. 2007a, b, c; Shahbaaz et al. 2015) and dis-
covery and CAVA is considered as a potential drug target,
and some of its inhibitors may lead to the development of
novel anti-obesity therapies (Arechederra et al. 2013; De
Fig. 4 a Western blot analysis confirmed the presence of recombinant CAVA protein. b Peptide mass fingerprint of CAVA
Fig. 5 Far-UV CD spectra of recombinant protein CAVA. Curves 1,
2 and 3 represent spectra of denatured, renatured and native proteins,
respectively
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Simone and Supuran 2007). Furthermore, structure analysis
with docking and MD simulation will further guide to
design a potent and selective inhibitor of CAV which will
be validated experimentally.
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